Maurie Markman, MD

Maurie Markman, MD, discusses the essential yet often complex role associated with interpreting numbers and measurements in oncology.

Maurie Markman, MD, discusses the role of decision support tools in cancer management.

Maurie Markman, MD, discusses the evolving role of measurements in cancer care.

Maurie Markman, MD, details the lessons learned following results from older clinical trials within the oncology space.

Maurie Markman, MD, discusses the evolution of surgical oncology, from radical resections to multidisciplinary, minimally invasive, and neoadjuvant approaches.

Maurie Markman, MD, discusses the need to reevaluate how adverse effects are measured and reported with antineoplastic therapies in oncology.

Maurie Markman, MD, discusses future research considerations in gynecologic oncology.

Maurie Markman, MD, raises concerns about public health priorities and resource allocation in light of the expanding role of precision medicine in cancer.

Maurie Markman, MD, discussed the significance of patient-reported outcomes from the phase 3 OUTBACK trial in locally advanced cervical cancer.

Maurie Markman, MD, explores the key role of clinical judgment in treatment decision-making and its impact on patient outcomes in cancer research.

Maurie Markman, MD, discusses the complexities of cancer care financing in the US, highlighting the need for innovative solutions amidst rising costs.

Maurie Markman, MD, discusses the potential to shift the focus of cancer research towards the "real high technology of medicine", such as cancer vaccines.

The evolution of biomedical research continues to pose quite thorny ethical dilemmas.

Maurie Markman, MD, discusses the differences between prognostic vs predictive factors and their clinical utility in oncology practice.

Maurie Markman, MD, delves into questions regarding precision medicine and genetic testing in cancer.

Is it time to end the rhetoric that denies the benefit of antineoplastic pharmaceutical agents due to the absence of an OS improvement in a clinical trial?

Serious questions must be asked about the current state of interventional trials in the oncology sphere and how to improve their future value.

The oncology community must reconsider its approach to defining optimal dosing and scheduling of antineoplastic agents.

The speed at which new drugs, combinations, and novel approaches are being introduced into routine practice presents a challenge for treating oncologists

Maurie Markman, MD, details how the precision-medicine paradigm is a highly rational platform for antineoplastic drug development.

Maurie Markman, MD, discusses concerns regarding the scientific validity of peer-reviewed publications in oncology and their ramifications for the field.

Maurie Markman, MD, discusses an analysis of the association between obesity and the development of endometrial cancer.

Maurie Markman, MD, details the concept of hope during cancer diagnoses, touching on the announcement from Catherine, Princess of Wales.

Defining the goals of a clinical team within a cancer program or oncology practice group, where the focus will be on maximizing QOL, may be difficult.

Maurie Markman, MD, expands on the debate regarding the appropriate primary outcome end point for improved clinical benefit in a trial.

Randomized trials are widely recognized to play a pivotal role in the decision-making associated with the establishment of clinical guidelines.

Two items in the medical world should send chills down the spines of those considering the possible financial future of oncology care in the United States.

The foundation of physician recommendations and medical/regulatory policy will be guided by the outcomes of published clinical research.